Protocol Ledger

NCT05692999 · Phase III · RECRUITING

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

Interventional Phase III clinical trial protocol NCT05692999 sponsored by Gustave Roussy, Cancer Campus, Grand Paris in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-20 Enrollment: 1,166 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05692999
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,166 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05692999
Protocol FieldVerified Registry Value
NCT IdentifierNCT05692999
Consolidated Lead SponsorGustave Roussy, Cancer Campus, Grand Paris
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,166 participants (ESTIMATED)
Registered Start Date2023-03-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05692999
Hospital Research SiteLocationSite Profile
Institut Gustave RoussyVillejuif, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI